201 related articles for article (PubMed ID: 37040361)
1. Adeno-Associated virus 8 delivers an immunomodulatory peptide to mouse liver more efficiently than to rat liver.
Wang Y; Hurley A; De Giorgi M; Tanner MR; Hu RC; Pennington MW; Lagor WR; Beeton C
PLoS One; 2023; 18(4):e0283996. PubMed ID: 37040361
[TBL] [Abstract][Full Text] [Related]
2. Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases.
Beeton C; Pennington MW; Norton RS
Inflamm Allergy Drug Targets; 2011 Oct; 10(5):313-21. PubMed ID: 21824083
[TBL] [Abstract][Full Text] [Related]
3. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases.
Beeton C; Pennington MW; Wulff H; Singh S; Nugent D; Crossley G; Khaytin I; Calabresi PA; Chen CY; Gutman GA; Chandy KG
Mol Pharmacol; 2005 Apr; 67(4):1369-81. PubMed ID: 15665253
[TBL] [Abstract][Full Text] [Related]
4. Potassium channel blockade by the sea anemone toxin ShK for the treatment of multiple sclerosis and other autoimmune diseases.
Norton RS; Pennington MW; Wulff H
Curr Med Chem; 2004 Dec; 11(23):3041-52. PubMed ID: 15578998
[TBL] [Abstract][Full Text] [Related]
5. N-Terminally extended analogues of the K⁺ channel toxin from Stichodactyla helianthus as potent and selective blockers of the voltage-gated potassium channel Kv1.3.
Chang SC; Huq R; Chhabra S; Beeton C; Pennington MW; Smith BJ; Norton RS
FEBS J; 2015 Jun; 282(12):2247-59. PubMed ID: 25864722
[TBL] [Abstract][Full Text] [Related]
6. Development of highly selective Kv1.3-blocking peptides based on the sea anemone peptide ShK.
Pennington MW; Chang SC; Chauhan S; Huq R; Tajhya RB; Chhabra S; Norton RS; Beeton C
Mar Drugs; 2015 Jan; 13(1):529-42. PubMed ID: 25603346
[TBL] [Abstract][Full Text] [Related]
7. Role of disulfide bonds in the structure and potassium channel blocking activity of ShK toxin.
Pennington MW; Lanigan MD; Kalman K; Mahnir VM; Rauer H; McVaugh CT; Behm D; Donaldson D; Chandy KG; Kem WR; Norton RS
Biochemistry; 1999 Nov; 38(44):14549-58. PubMed ID: 10545177
[TBL] [Abstract][Full Text] [Related]
8. Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes.
Pennington MW; Beeton C; Galea CA; Smith BJ; Chi V; Monaghan KP; Garcia A; Rangaraju S; Giuffrida A; Plank D; Crossley G; Nugent D; Khaytin I; Lefievre Y; Peshenko I; Dixon C; Chauhan S; Orzel A; Inoue T; Hu X; Moore RV; Norton RS; Chandy KG
Mol Pharmacol; 2009 Apr; 75(4):762-73. PubMed ID: 19122005
[TBL] [Abstract][Full Text] [Related]
9. ShK-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide.
Kalman K; Pennington MW; Lanigan MD; Nguyen A; Rauer H; Mahnir V; Paschetto K; Kem WR; Grissmer S; Gutman GA; Christian EP; Cahalan MD; Norton RS; Chandy KG
J Biol Chem; 1998 Dec; 273(49):32697-707. PubMed ID: 9830012
[TBL] [Abstract][Full Text] [Related]
10. Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases.
Chhabra S; Chang SC; Nguyen HM; Huq R; Tanner MR; Londono LM; Estrada R; Dhawan V; Chauhan S; Upadhyay SK; Gindin M; Hotez PJ; Valenzuela JG; Mohanty B; Swarbrick JD; Wulff H; Iadonato SP; Gutman GA; Beeton C; Pennington MW; Norton RS; Chandy KG
FASEB J; 2014 Sep; 28(9):3952-64. PubMed ID: 24891519
[TBL] [Abstract][Full Text] [Related]
11. A potent and selective peptide blocker of the Kv1.3 channel: prediction from free-energy simulations and experimental confirmation.
Rashid MH; Heinzelmann G; Huq R; Tajhya RB; Chang SC; Chhabra S; Pennington MW; Beeton C; Norton RS; Kuyucak S
PLoS One; 2013; 8(11):e78712. PubMed ID: 24244345
[TBL] [Abstract][Full Text] [Related]
12. Designed peptide analogues of the potassium channel blocker ShK toxin.
Lanigan MD; Pennington MW; Lefievre Y; Rauer H; Norton RS
Biochemistry; 2001 Dec; 40(51):15528-37. PubMed ID: 11747428
[TBL] [Abstract][Full Text] [Related]
13. Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease.
Tarcha EJ; Chi V; Muñoz-Elías EJ; Bailey D; Londono LM; Upadhyay SK; Norton K; Banks A; Tjong I; Nguyen H; Hu X; Ruppert GW; Boley SE; Slauter R; Sams J; Knapp B; Kentala D; Hansen Z; Pennington MW; Beeton C; Chandy KG; Iadonato SP
J Pharmacol Exp Ther; 2012 Sep; 342(3):642-53. PubMed ID: 22637724
[TBL] [Abstract][Full Text] [Related]
14. Selective Kv1.3 channel blocker as therapeutic for obesity and insulin resistance.
Upadhyay SK; Eckel-Mahan KL; Mirbolooki MR; Tjong I; Griffey SM; Schmunk G; Koehne A; Halbout B; Iadonato S; Pedersen B; Borrelli E; Wang PH; Mukherjee J; Sassone-Corsi P; Chandy KG
Proc Natl Acad Sci U S A; 2013 Jun; 110(24):E2239-48. PubMed ID: 23729813
[TBL] [Abstract][Full Text] [Related]
15. Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis.
Beeton C; Wulff H; Barbaria J; Clot-Faybesse O; Pennington M; Bernard D; Cahalan MD; Chandy KG; Béraud E
Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13942-7. PubMed ID: 11717451
[TBL] [Abstract][Full Text] [Related]
16. Kv1.3 Channel as a Key Therapeutic Target for Neuroinflammatory Diseases: State of the Art and Beyond.
Wang X; Li G; Guo J; Zhang Z; Zhang S; Zhu Y; Cheng J; Yu L; Ji Y; Tao J
Front Neurosci; 2019; 13():1393. PubMed ID: 31992966
[TBL] [Abstract][Full Text] [Related]
17. Chemical synthesis and characterization of ShK toxin: a potent potassium channel inhibitor from a sea anemone.
Pennington MW; Byrnes ME; Zaydenberg I; Khaytin I; de Chastonay J; Krafte DS; Hill R; Mahnir VM; Volberg WA; Gorczyca W
Int J Pept Protein Res; 1995 Nov; 46(5):354-8. PubMed ID: 8567178
[TBL] [Abstract][Full Text] [Related]
18. Conformational exchange in the potassium channel blocker ShK.
Iwakawa N; Baxter NJ; Wai DCC; Fowler NJ; Morales RAV; Sugase K; Norton RS; Williamson MP
Sci Rep; 2019 Dec; 9(1):19307. PubMed ID: 31848433
[TBL] [Abstract][Full Text] [Related]
19. Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases.
Chi V; Pennington MW; Norton RS; Tarcha EJ; Londono LM; Sims-Fahey B; Upadhyay SK; Lakey JT; Iadonato S; Wulff H; Beeton C; Chandy KG
Toxicon; 2012 Mar; 59(4):529-46. PubMed ID: 21867724
[TBL] [Abstract][Full Text] [Related]
20. A bioengineered probiotic for the oral delivery of a peptide Kv1.3 channel blocker to treat rheumatoid arthritis.
Wang Y; Zhu D; Ortiz-Velez LC; Perry JL; Pennington MW; Hyser JM; Britton RA; Beeton C
Proc Natl Acad Sci U S A; 2023 Jan; 120(2):e2211977120. PubMed ID: 36595694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
